knowledge
A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.
Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.
advertisement
Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Previous article：
After a decade, new Gardasil ad campaign gets it (mostly) right
Next article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Duchenne breakthrough therapy leaves behind pioneering families
